Stella Diagnostics Announces Partnership with mProbe Laboratories
Stella Diagnostics (OTC PINK:JMDP) has partnered with mProbe, Inc. to enhance its proteomic biomarker panel for detecting precancerous esophageal tissues. This collaboration aims to validate the STLA101 panel designed to predict the risk of Barrett's esophagus progressing to esophageal cancer. Clinical samples will be analyzed to assess the panel's effectiveness, with results expected to be shared at major medical conferences. This initiative aims to improve patient management for the 67 million Americans suffering from severe esophageal conditions.
- Partnership with mProbe to enhance diagnostic capabilities.
- Development of STLA101 panel to detect precancerous conditions.
- Plans to submit findings to leading oncology and gastroenterology conferences.
- Esophageal cancer incidence has increased 700% over the last four decades.
- Average survival rate of EAC is just 13 months post-diagnosis.
PALO ALTO, CA / ACCESSWIRE / February 4, 2021 / Stella Diagnostics, Inc. (OTC PINK:JMDP) ("Stella" or "The Company") announced today that they have entered into a partnership with mProbe, Inc., a leading biotechnology company based in California. The aims of the partnership were to build, optimize and further validate Stella's novel panel of proteomic biomarkers designed to detect and quantify proto-oncogenes present in precancerous esophageal tissues. mProbe's CAP-accredited and CLIA-certified laboratory in Maryland has performed landmark research with a focus on transforming the field of Precision Medicine, Precision Health, and Predictive Healthcare Analytics utilizing its cutting-edge proprietary multi-omics platform.
The Company's STLA101 proteomic panel for predicting the risk of Barrett's esophagus progressing to esophageal cancer has been built by mProbe and optimization is in progress. Stella and mProbe will be receiving clinical samples from multiple renowned medical institutions to assess the specificity, sensitivity, predictability and clinical utility of the panel. Stella plans to submit, along with their clinical collaborators, the findings of these studies to leading oncology and gastroenterology conferences and journals over the next two years.
Dr. Joe Abdo, the CEO of Stella Diagnostics: "mProbe has been a mainstay in the cancer diagnostics space for over a decade and we could not be working with a better team of scientists and clinicians to help build out and optimize our product candidates. Our mission at Stella is to stratify patients by disease severity with our multi-pronged biochemical approach. In doing so, high risk patients shall be identified at the disease onset when it is most treatable. We are very excited about the collaborative partnership with mProbe in assessing every aspect of our novel diagnostic panels."
Dr. Sheeno Thyparambil, the Senior Director of Research at mProbe stated, "Stella Diagnostics has developed oncology-specific molecular diagnostics panels that have the potential to help physicians optimize how they screen and/or treat millions of patients with precancerous or malignant diseases of the lower esophagus. Although not well publicized or broadly discussed, esophageal disease is increasing at an enormous rate in the US. Working with Stella affords us the opportunity to potentially help those patients."
Barrett's esophagus is the only known precursor to esophageal adenocarcinoma (EAC) and these patients have a 125-fold higher risk of developing cancer of the lower esophagus. The incidence rate of EAC has increased
About Stella Diagnostics
Stella Diagnostics, Inc. is a molecular diagnostics-based organization focused on improving patient management strategies for over 67 million people living with severe esophageal disease. StellaDX's clinical assay will offer physicians insight into the molecular properties of their patients' tissue to determine if the disease is stable, progressing or turning cancerous. Using targeted mass spectrometry proteomics, we believe that informing physicians of the expression patterns playing a role in the pathogenesis of GERD, Barrett's esophagus and esophageal cancer early in the treatment plan may extend or save lives. For more information, please visit www.stelladx.com.
About mProbe
mProbe Inc. is a leading biotechnology company based in California and committed to promoting human health and wellness by transforming the field of Precision Medicine, Precision Health, and Predictive Healthcare Analytics. mProbe has developed a proprietary technology platform integrating artificial intelligence and multi-omic diagnostics to transform the disease prediction, prevention, and cure paradigm. For more information, please visit www.mprobe.com.
Investors and Media Contact:
Stella Diagnostics, Inc.
Email: info@stelladx.com
Phone: 201-381-1474
mProbe, Inc.
Email: info@mprobe.com
Phone: 650-512-0108
SOURCE: Stella Diagnostics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/627818/Stella-Diagnostics-Announces-Partnership-with-mProbe-Laboratories
FAQ
What is the recent partnership announced by Stella Diagnostics (JMDP)?
What is the purpose of the STLA101 proteomic panel?
How has esophageal cancer incidence changed in recent years?
What are the survival rates for esophageal adenocarcinoma?
Where will findings from the Stella Diagnostics and mProbe partnership be presented?
